Mind Medicine (NASDAQ:MNMD) Stock, Quote.Headers.trade-ideas

Mind Medicine

Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.

Cannabis

News

Psychedelics

Press Releases

ABBV

ATAI

CMPS

COMP

MNMD

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.

Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration

MindMed_healthcare_setting

Markets

Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M

image006

Exclusives

CSE:HAVN

CSE:TRIP

CYBN

HAVLF

MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC.

MYCOF

RVVTF

SEEL

TRIP

RED LIGHT HOLLAND CORP by Red Light Holland Corp.

TRUFF

Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine Inc

MANDO MACHINERY GDR

Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the upcoming late-breaking presentation related to ATR-04. The presentation by Dr. Mary Spellman will take place on Thursday, September 26, 2024, in a late-breaking oral session entitled "Development of a Staphylococcus epidermidis strain for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity" at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam.
ATR-04 is a live biotherapeutic product candidate consisting of an S. epidermidis strain that was isolated from a healthy volunteer and engineered to be safer by deleting an antibiotic resistance gene and engineering auxotrophy to control the growth of ATR-04. ATR-04 is in development for EGFRi-associated skin toxicity, which is caused by the suppression of skin immunity by EGFRis and subsequent inflammation and often elevated levels of IL-36γ and S. aureus. There are approximately 150,000 patients suffering from EGFRi-induced skin toxicity in the United States. Azitra has an active IND for a multicenter, randomized, controlled Phase 1/2 clinical trial of ATR-04 in patients with dermal toxicity due to EGFR inhibitors, and ATR-04 has received Fast Track designation from the FDA.

Biotech

General

AZTR

Azitra Announces Late-Breaking Presentation Related To ATR-04 At The EADV Congress

-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA- &nbsp;
-Initial Label Would Include All Patients with Cardiomyopathy Associated with Duchenne Muscular Dystrophy-
-Rolling Submission Planned to Commence in October 2024-
-Internal GMP Manufacturing Established to Support BLA and Commercialization-
-Investor Webcast Today at 8:30 a.m. ET-
SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Dn3dPseyoYpJ2ydS9_fKGSY-L8y3j-58USJTWl-wU8dEA89PRS2JOkAnKJH6HgHxdaGntPImf1dAz10xwns5wWVF-ZkWxrG06hwj8W1ppJwm2PvCg47N6tUBYJpNjbU7XS0hd4gSdWmh8IMvOyGDntkraCOIdeb3sopV9B8ltkAflERhFEgZ-cOYB1pUfS5ZLkQMHm1eaJzMqxKEqbLfCNWU4f8b3VresJn-vaFF3zxYWk3KnleejbWgj8uh5dJg75izbevazWgAZXmJqhdVow==">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today, following recent meetings with the U.S. Food and Drug Administration (FDA), its intent to file a Biologics License Application (BLA) based on existing cardiac and natural history data for deramiocel to treat all patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.

CAPR

Capricor Therapeutics Announces Intent To File Biologics License Application For Full Approval Of Deramiocel For The Treatment Of Duchenne Muscular Dystrophy Cardiomyopathy

WIIM

Merrill Lynch & Strategic Return Notes for Select 10 Index

Maison Solutions shares are trading higher after the company reported a year-over-year increase in Q1 sales results.

Benchmark analyst Subash Chandra maintains Sable Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) with a Buy and raises the price target from $24 to $37.

Price Target

Analyst Ratings

Benchmark Maintains Buy on Sable Offshore, Raises Price Target to $37

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares closed slightly<a href="https://www.benzinga.com/quote/NVDA"> higher on Monday</a>.
The company's CEO, Jensen Huang, has underscored the potential of artificial intelligence (AI) in reshaping India&#8217;s technological landscape, adding that it <a href="https://www.benzinga.com/news/24/09/40974645/nvidia-ceo-jensen-huang-meets-pm-modi-says-its-indias-moment-amid-ai-boom">was &#8220;India&#8217;s moment&#8221;.</a>
Huang&#8217;s comments came following his meeting with Indian Prime Minister Narendra Modi during the latter&#8217;s three-day U.S. visit, which concluded on Monday. Huang was among the 15 tech leaders who had the opportunity to engage with the prime minister.
With the recent buzz around NVIDIA, some investors may be eyeing potential gains from the company's dividends. As of now, NVIDIA has a dividend yield of 0.03%, which is a quarterly dividend amount of 1 cent a share (4 cents a year).
To figure out how to earn $500 monthly from NVIDIA, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by NVIDIA's $1.00 dividend: $6,000 / $0.04 = 150,000 shares
So, an investor would need to own approximately $17,439,000 worth of NVIDIA, or 150,000 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.04 = 30,000 shares, or $3,487,800 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
NVDA Price Action: Shares of Nvidia gained 0.2% to close at $116.26 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40980672/top-3-financials-stocks-that-may-plunge-in-september">Top 3 Financials Stocks That May Plunge In September</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Tech

Trading Ideas

NVDA

How To Earn $500 A Month From NVIDIA Stock

Across the recent three months, 7 analysts have shared their insights on Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.86, a high estimate of $21.00, and a low estimate of $12.00. Observing a downward trend, the current average is 8.86% lower than the prior average price target of $18.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1727179279_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Crescent Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$16.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Crescent Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crescent Energy compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Crescent Energy's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Crescent Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CRGY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Crescent Energy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Crescent Energy</h2>
Crescent Energy Co an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key proven basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non‐operated assets, mineral and royalty interests, and midstream infrastructure.
<h3>A Deep Dive into Crescent Energy's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Crescent Energy displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 32.69%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Crescent Energy's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.75%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Crescent Energy's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.84%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.53%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Crescent Energy's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.18, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRGY

Evaluating Crescent Energy: Insights From 7 Financial Analysts

15 analysts have expressed a variety of opinions on Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sunrun, revealing an average target of $23.3, a high estimate of $38.00, and a low estimate of $16.50. This current average has increased by 13.83% from the previous average price target of $20.47. 
<img src="https://www.benzinga.com/files/images/story/2024/1727179269_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Sunrun is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Corinne Blanchard</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$16.50</td>
<td>$12.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sunrun. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sunrun compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Sunrun's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sunrun's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RUN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sunrun analyst ratings.</a>
<h2>Discovering Sunrun: A Closer Look</h2>
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed either by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
<h3>Sunrun: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: Sunrun's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -11.24%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Sunrun's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.72% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sunrun's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.65%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sunrun's ROA excels beyond industry benchmarks, reaching 0.66%. This signifies efficient management of assets and strong financial health.
Debt Management: Sunrun's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.25, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 15 Analyst Recommendations For Sunrun

Ratings for TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated TransMedics Gr and provided 12-month price targets. The average target is $184.22, accompanied by a high estimate of $208.00 and a low estimate of $145.00. Observing a 29.6% increase, the current average has risen from the previous average price target of $142.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1727179258_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive TransMedics Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$208.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$208.00</td>
<td>-</td>
</tr>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$169.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to TransMedics Gr. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TransMedics Gr compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of TransMedics Gr's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into TransMedics Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TMDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TransMedics Gr analyst ratings.</a>
<h2>Discovering TransMedics Gr: A Closer Look</h2>
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
<h3>Financial Insights: TransMedics Gr</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: TransMedics Gr's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 117.87%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: TransMedics Gr's net margin excels beyond industry benchmarks, reaching 10.67%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): TransMedics Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.98%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.65%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 2.72, TransMedics Gr faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TMDX

Expert Ratings For TransMedics Gr

Analysts' ratings for First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for First Citizens BancShares, revealing an average target of $2212.5, a high estimate of $2300.00, and a low estimate of $2150.00. This current average has increased by 4.73% from the previous average price target of $2112.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1727179244_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of First Citizens BancShares's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2150.00</td>
<td>$2450.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$2250.00</td>
<td>$1950.00</td>
</tr>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2150.00</td>
<td>$1950.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$2300.00</td>
<td>$2100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to First Citizens BancShares. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of First Citizens BancShares compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of First Citizens BancShares's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of First Citizens BancShares's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FCNCA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on First Citizens BancShares analyst ratings.</a>
<h2>Get to Know First Citizens BancShares Better</h2>
First Citizens BancShares Inc is the bank holding company of First Citizens Bank &amp; Trust Company. FCB was founded as the Bank of Smithfield in North Carolina and has expanded through both de novo branching and acquisitions. FCB currently operates in nearly half of the continental United States, but principally takes deposits in the Carolinas. The bank's operations have historically been influenced by the Holding family, which has traditionally held executive and director positions, as well as controlling a large percentage of its outstanding stock. FCB provides a wide range of retail and commercial banking services, including traditional lending and deposit-taking, as well as trust and wealth management. FCB's main source of revenue is net interest income.
<h3>Unraveling the Financial Story of First Citizens BancShares</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining First Citizens BancShares's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -4.27% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: First Citizens BancShares's net margin excels beyond industry benchmarks, reaching 28.82%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): First Citizens BancShares's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.25%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.32%, the company showcases effective utilization of assets.
Debt Management: First Citizens BancShares's debt-to-equity ratio stands notably higher than the industry average, reaching 1.73. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCNCA

Cracking The Code: Understanding Analyst Reviews For First Citizens BancShares

Across the recent three months, 5 analysts have shared their insights on Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $5.2, a high estimate of $6.00, and a low estimate of $5.00. Observing a downward trend, the current average is 7.14% lower than the prior average price target of $5.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1727179230_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Taboola.com's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Taboola.com. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Taboola.com compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Taboola.com's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Taboola.com's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TBLA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Taboola.com analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Taboola.com Better</h2>
Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, Germany, France, Rest of the world whilst it generates the majority of its revenue from the United States.
<h3>Taboola.com's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Taboola.com showcased positive performance, achieving a revenue growth rate of 28.96% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.0%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Taboola.com's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.42%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Taboola.com's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Taboola.com's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.21.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TBLA

Analyst Ratings For Taboola.com

On Tuesday, Guardforce AI Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAIW#NASDAQ">GFAIW</a>) reported financial results and provided a business update for the first half of 2024 ended June 30, 2024.
Net revenue decreased by 2.4% year-on-year to $17.6 million in for the six months ended 2024, mainly due to reduced foreign currency exchange rates between Thai Baht and U.S. Dollars.
Despite the impact of foreign currency exchange rates, revenue for the secured logistics business increased by 5.2% year over year.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/08/40392173/exclusive-guardforce-ai-deploys-advertising-robots-in-new-york-prepares-to-launch-spatial-computing" rel="noreferrer noopener">EXCLUSIVE: Guardforce AI Deploys Advertising Robots in New York, Prepares To Launch Spatial Computing Tech</a>
Gross profit increased by 50% Y/Y to $3.2 million, driven partly by an improvement in gross profit margin, which increased 18.4% by 640 bps Y/Y.
Gross profit margin growth reflected cost control initiatives and a higher profit margin from its continued growing GDM business and Cash-In-Transit business with its retail customers.
Adjusted net income was $0.1 million for the six months ended June 2024 compared to an adjusted net loss of $1.8 million a year ago.
Selling, distribution, and administrative expenses decreased 25.7% year over year to $5.0 million. Operating loss improved by 82.5% year over year to $2.1 million, mainly due to reduced fixed asset depreciation and inventory provisions.
As of June 30, 2024, the company had $15.5 million in cash and equivalents.
Chair and CEO Lei (Olivia) Wang stated, &#8220;Our primary focus is developing GFAI Agents, which serve as the key technological backbone for our AI-driven travel and purchase solutions. By concentrating on high-margin services within the retail and travel sectors, alongside implementing cost-control initiatives, we&#8217;ve achieved notable results. We expanded services to over 25,000 retail stores, turned adjusted net income positive, and achieved an approximately 50.0% increase in gross profit in H1 2024 compared to H1 2023.&#8221;
Guardforce consolidated legacy business by securing long-term contracts with key clients, driving growth in higher-margin solutions.
Guardforce Cash Solutions Security (Thailand) Company (GFCS) won a 5-year contract to operate a Consolidate Cash Center (CCC) in Chiang Mai, Thailand. The company will become the largest CCC operator on behalf of the Bank of Thailand, operating 50% of its CCC operations.
Beijing Wanjia Security System Limited secured two long-term contracts with existing key clients, expanding security alarm solutions to an additional 3,900 stores, representing an over 50% increase year over year and bringing the total number of stores serviced to 12,000 across Mainland China.&nbsp;
The total number of retail stores served in the security sector surpassed 25,000.
Guardforce developed GFAI Agents as the core technology foundation for AI Purchase and AI Travel Solutions.
The company launched a decentralized spatial computing solution that utilizes robots&#8217; unused computing power to process complex tasks beyond advertising.
Price Action: GFAI stock closed higher by 0.88% at $1.15 on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39811868/exclusive-guardforce-ai-secures-new-contracts-with-top-retail-brands-boosts-operations" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Guardforce AI Secures New Contracts with Top Retail Brands, Boosts Operations</a></li>
</ul>

Earnings

Market-Moving Exclusives

GFAI

GFAIW

EXCLUSIVE: Guardforce H1'24 Earnings: 50% Jump in Gross Profit, Turns Net Income Positive, Expands AI Solutions

Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has been in the news lately. However, it was not for what it did but for what it didn't do. Unlike prior sessions when the technology juggernaut – whose advanced graphics processors are critical for artificial intelligence – seemingly enjoyed no upside limits, NVDA stock has recently lost some of its shine. In the past five business days, shares have lost about 2% of equity value.
In the trailing month, NVDA stock finds itself below parity to the tune of 8%. Part of the reason could come down to temporary exhaustion. While the<a href="https://www.benzinga.com/quote/NVDA"> majority of the 37 analysts</a> covering Nvidia in the past four months have rated the equity a "Buy," the tech giant is noticeably losing steam. For example, quarter-to-quarter revenue growth has declined from 22% in Q4 of fiscal 2024 to 15% in Q2 of fiscal 2025.
That's not to say that NVDA stock is devoid of opportunity. Recently, Nvidia partnered with Alibaba Group Holding's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) cloud-computing services unit to help<a href="https://www.benzinga.com/government/24/09/40977069/alibaba-teams-up-with-nvidia-to-supercharge-evs-for-chinese-automakers-report"> augment the autonomous driving experience</a> for several of China's smart vehicle enterprises. According to Grand View Research, the global automotive AI market reached a<a href="https://www.grandviewresearch.com/industry-analysis/automotive-artificial-intelligence-market-report"> valuation of $2.99 billion in 2022</a>.
Nevertheless, the options market seems to have priced in the recent slowdown in NVDA stock, with<a href="https://www.barchart.com/stocks/quotes/NVDA"> implied volatility (IV) currently sitting at 44.56%</a>. In contrast, historical volatility clocks in at 59.03%. Notably, as Benzinga's Aniket Verma mentioned, early in September,<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40705236/as-nvidia-and-bitcoin-falter-amid-market-meltdown-which-asset-is-set-for-bigger-price-swin"> IV stood at 55%</a>. Stated differently, the derivatives arena is anticipating lower-than-normal volatility.
Significantly, when the market projects lower magnitude of movement, the premiums on options become relatively discounted. Therefore, an<a href="https://www.investopedia.com/terms/i/iv.asp#:~:text=Conversely%2C%20if%20a%20trader%20believes,might%20choose%20to%20buy%20options."> incentive</a> exists to buy both call and put options, presenting an intriguing framework for exchange-traded funds. As more traders speculate on NVDA options, demand for other derivative products – including leveraged ETFs – may rise.
The Direxion ETFs: One of the key providers of financial products, Direxion forged a strong reputation over the past several years through its leveraged ETFs. Using a variety of instruments such as swaps and futures contracts, the company is able to provide an extra kick to its basket of securities.
The Direxion Daily NVDA Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDU#NASDAQ">NVDU</a>) focuses specifically on NVDA stock. Primarily, the attribute for NVDU is its upside potential, which aims for 200% of the daily performance of Nvidia shares. On the other end of the scale, the Direxion Daily NVDA Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDD#NASDAQ">NVDD</a>) aims for 100% of the inverse performance of NVDA.
Whichever fund investors choose, they must be aware of an important caveat: neither ETF is designed for exposure lasting longer than one day. Those that ignore this guidance risk incurring volatility drag (or decay). This phenomenon refers to the erosion of returns due to the daily compounding effect.
The NVDU ETF: Since the beginning of the year, the NVDU ETF gained more than 220%, a remarkable performance that continues to tempt would-be speculators.
<ul>
<li>Although a popular leveraged fund, NVDU's momentum has slowed significantly, gaining "only" 21.5% in the past six months.</li>
<li>Currently, the ETF is sandwiched between the 50-day moving average at top and the 200 DMA below.</li>
<li>It's possible that from April of this year onward, the market may be charting a bullish pennant formation.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXdn33VU35yLn4PnUt-hjanmerb-1Miw8ljQUejV4GNfd-LomE-hpQD7ejZ9w3yWOzuksHo-htTtV_x1QseFzfr9QKv3r9i_weEKzH_gSF4w5-E2S4KDxaJoov0Ayfu_PZRXuqwTM2x73rMAdbL9xItUxwHh?key=06BcLMCphxmpbfelY6BI8A" alt="" /></figure>
The NVDD ETF: In sharp contrast to NVDU's good fortunes, the inverse NVDD fund has struggled, losing 66% since the beginning of January.
<ul>
<li>While not the most compelling opportunity, NVDD has started to look interesting recently, with the inverse ETF rising over 6% in the past month.</li>
<li>Nevertheless, a significant challenge awaits the bears, with NVDD finding itself below its 50 and 200 DMAs.</li>
<li>The inverse fund has consistently bounced off the horizontal support line represented by the $7.50 level, raising intrigue for the pessimistic case.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXdi4GnnfcjtGof9U6at_RiHwrWnX12EacfFYosIyrsTn-7R6mF7w_ZFO0kMQs3dzdFK9Mj181FcTWCwCmWt0kIIVnWmx0FwXHwTM951M9WI64ljpB7mdbIiDXLdAoOiLEF3CdTGu03yXwOimdVYY3cF_Nk?key=06BcLMCphxmpbfelY6BI8A" alt="" /></figure>
Featured photo by<a href="https://www.pexels.com/@jord/"> Jordan Harrison</a> from<a href="https://www.pexels.com/photo/gray-laptop-computer-343239/"> Pexels</a>.

Short Ideas

Technicals

ETFs

BABA

NVDD

NVDU

A Potential Calm Before The Storm Could Draw Intrigue In Direxion's NVDU And NVDD Funds

In the latest quarter, 34 analysts provided ratings for Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Salesforce and provided 12-month price targets. The average target is $304.62, accompanied by a high estimate of $350.00 and a low estimate of $236.00. This upward trend is apparent, with the current average reflecting a 4.41% increase from the previous average price target of $291.76.
<img src="https://www.benzinga.com/files/images/story/2024/1727179221_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Salesforce by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$268.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$345.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Hold</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$345.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Ambrish Shah</td>
<td>Phillip Securities</td>
<td>Announces</td>
<td>Accumulate</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Mark Moerdler</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$290.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Richard Baldry</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$335.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$320.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$305.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$268.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$350.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$316.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$270.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$345.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$342.00</td>
<td>$342.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$316.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Salesforce. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Salesforce compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Salesforce's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Salesforce's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CRM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Salesforce analyst ratings.</a>
<h2>Get to Know Salesforce Better</h2>
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
<h3>Financial Insights: Salesforce</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Salesforce displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 8.39%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Salesforce's net margin is impressive, surpassing industry averages. With a net margin of 15.32%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.44%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.52%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Salesforce Analyst Ratings: What You Need To Know

EXCLUSIVE: Guarforce AI Tells Benzinga 'Gross profit increased 50% in H1 2024 compared to H1 2023'

EXCLUSIVE: Guardforce AI Tells Benzinga Co. Reports Positive Adjusted Net Income For The First Half Of 2024

Benchmark analyst Bruce Jackson reiterates NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy and maintains $18 price target.

Reiteration

Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target

Generations Bancorp NY, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBNY#NASDAQ">GBNY</a>) shares are trading higher premarket Tuesday. The company agreed to sell most of its assets and liabilities, including deposits, to ESL Federal Credit Union <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40996832/rochester-based-esl-federal-credit-union-announces-acquisition-of-generations-bank" rel="noreferrer noopener">for $26.2 million in cash</a>.
Generations Bank will retain its equity at the effective time of the P&amp;A transaction, with some adjustments.
The Boards of Directors of ESL Federal Credit Union and Generations unanimously approved the transaction.
After settling all obligations, Generations Bank will liquidate, and Generations Bancorp will distribute its assets to shareholders in two payments.
Shareholders are estimated to receive between $18.00 and $20.00 per share, with the majority expected within six to nine months after the transaction closes, and the remainder six to nine months after the first payment.
The sale is expected to close in the late second quarter or third quarter of 2025, pending regulatory and shareholder approvals and other conditions.
Currently, Generations Bancorp has 2.24 million outstanding shares. Eligible depositors from Generations&#8217; second-step conversion may receive liquidation payments.
The transaction allows ESL Federal Credit Union to expand in the Greater Rochester and Finger Lakes region, growing to $9.6 billion in assets and over 30 branches across Seneca, Cayuga, Orleans, and Ontario Counties.
Faheem Masood, President and Chief Executive Officer of ESL Federal Credit Union, said, &#8220;This deal is a strong fit for ESL and Generations because both organizations are committed and dedicated to serving their employees, customers and their communities.&#8221;
In a separate statement, Generations Bancorp NY announced its voluntary decision to delist its common stock from Nasdaq and its intent to deregister its common stock with the SEC.
Following delisting from Nasdaq, the company expects its common stock to be quoted on the OTCQX Market beginning on&nbsp;October 7, 2024, <a target="_blank" href="https://www.benzinga.com//node/40997249" rel="noreferrer noopener">and expects to retain the symbol &#8220;GBNY.&#8221;</a>
Price Action: GBNY shares are up 39.5% at $15.35 premarket at the last check Monday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/40996656" target="_blank" rel="noreferrer noopener">Visa Reportedly Faces DOJ Antitrust Lawsuit Alleging Monopolization Of US Debit Card Market Amid Regulatory Crackdown</a></li>
</ul>

Equities

Small Cap

Movers

GBNY

Generations Bancorp's $26.2M Sale To ESL Federal: Big Payouts Await Shareholders As Bank Prepares For Liquidation

VBFC

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

ALTM

AMLI

Shares of lithium companies are trading higher after China Central Bank announced a new stimulus package.

SCCO

TECK

Shares of copper stocks are trading higher after China Central Bank announced a new stimulus package.

Mind Medicine: Pumping Up The Balance Sheet (Again)

Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report

Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past week.

Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week

Mind Medicine (MNMD) has released an update. Mind Medicine (MindMed) Inc., a biopharmaceutical company focusing on brain health disorders, will be ...

MindMed Showcases Innovation at Investor Events

Stock Picks From Seeking Alpha's August 2024 New Analysts

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.

Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August

Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are having growing pains.

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th

Mind Medicine (MNMD) has released an update. Mind Medicine (MindMed) Inc., a biopharmaceutical company focused on brain health disorders, has annou...

MindMed Issues New Employee Share Options

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week

ABNB

ATNF

BAMXF

BMWYY

BRBOF

BRBOY

BTSG

BTSGU

BYMOF

CHGG

CLFD

CLPR

CMND

DRUG

ENVB

FLTLF

FRCOF

FRCOY

GHRS

GILD

INTC

IREN

LULU

MANH

MGPI

MMDCF

NIOIF

NTSGF

REPYF

REPYY

ROAD

RTMVF

RTMVY

SATS

SPRC

SWGAF

SWGAY

SWGNF

TSX:AUM

VEOEF

VEOEY

VGSH

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Mind Medicine

Mind Medicine (MNMD) Forecast

Mind Medicine (NASDAQ:MNMD) Stock, Quote.Headers.trade-ideas